Last Updated on December 31, 2023 by The Health Master
Download the notification No. S.O. 4002(E) dated 14-08-2022, the link is given below: The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 45 drug formulations, vide notification No. S.O. 4002(E) dated 14-08-2022, which includes those used in the treatment of hypertension, the common cold, infections, acidity, and eye discomfort.
Fixation of retail prices of 45 drug formulations
Some drugs whose prices have been fixed are also used in treating high cholesterol and triglyceride levels.
The retail price of the combination of Paracetamol, Phenylephrine Hydrochloride, Caffeine & Diphenhydramine Hydrochloride tablets, for example, has been fixed at Rs 3.73. This combination is used in cases of allergies and the common cold.
Another combination whose price has been fixed at Rs 168.43 is Amoxycillin and Potassium Clavulanate Oral Suspension (used as an antibiotic).
Likewise, a formulation including Sitagliptin and Metformin Hydrochloride (sustained release) tablets, used in the treatment of diabetes, cannot cost more than Rs 18.67.
The prices of the drugs have been fixed under the Drug Price Control Order (2013), says the notification issued by the NPPA on August 24.
It also said manufacturers may add Goods and Services Tax (GST) only if they have paid it.
Growing net of fixed-dose combinations
The latest notification comes amid growing concerns that the number of fixed-dose drug combinations (FDCs), or pharma products which contain more than one active ingredient used for a particular indication, is increasing in the Indian market at a worrying rate.
These drugs are first granted approval by the Central Drugs Standard Control Organisation, after which they apply to the NPPA for retail price fixation.
Since October 2020, the NPPA had been highlighting its reservation over increasing regulatory approval for FDC medicines which are sometimes also referred to as drug cocktails.
Many pharmacologists have concurred that approval of these FDCs—many of which are sometimes unscientific — could compromise the rationale for the usage of the drugs, raise drug resistance, and may lead to over-medication.
Latest on National Pharmaceutical Pricing Authority (NPPA)
Latest notifications – DPCO / NPPA
Latest Notifications: EC Act (Essential Commodities Act)
FAQs – On DPCO: Drugs (Prices Control) Order, 2013
CDSCO panel wants justification on Protocol Amendments on Trail of Imlunestrant
USFDA gives nod for generic Carbamazepine tablets
FDA fixes upper limit for Wholesalers & Retailers for storage, sale of NDPS DRugs…
USFDA gives approval for this BP monitor device
Govt revises guidelines for PLI scheme domestic Medical Devices
UFDA issues Form 483 to Cipla’s facility in MP
Nicotine replacement therapy may become part of Essential Medicines List
Drug recall: Glenmark, Strides Pharma, Cipla recalled these drugs
DCGI approves olaparib as monotherapy for high-risk early breast cancer
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
